Home ultrasound has always been a promise that the healthcare industry struggled to keep — reliable imaging without a trained sonographer in the room remains one of obstetric care’s hardest unsolved problems. Pulsenmore just got a significant push toward cracking it. The medical device company announced it has received a $1.27 million grant from the Israel Innovation Authority for its SmartScan AI program, according to a PR Newswire release. What makes the timing striking: this is the company’s second AI grant approved in less than 30 days. For a company working at the intersection of consumer hardware and clinical-grade diagnostics, that back-to-back signal from a national innovation authority is hard to ignore. The broader race to embed AI infrastructure into specialized verticals is accelerating fast, and maternal health is emerging as one of the sectors where the stakes for getting it right are highest.
What SmartScan Is Actually Trying to Do
Pulsenmore’s core product is an FDA-cleared, at-home ultrasound device designed for use during pregnancy. The device attaches to a smartphone and allows expectant mothers to conduct fetal monitoring scans themselves, with the footage reviewed remotely by a clinician. The SmartScan AI program takes that concept further: it aims to embed AI guidance directly into the scanning process, helping untrained users capture diagnostically useful images in real time rather than relying entirely on post-scan clinical review.
That distinction matters enormously. The clinical value of a home ultrasound scan degrades sharply if the image quality is poor or if the probe was positioned incorrectly. By training AI to coach users through the scan as it happens — flagging angles, prompting repositioning, and confirming when a usable image has been captured — Pulsenmore is attempting to close the gap between consumer accessibility and clinical reliability. The $1.27 million grant will fund continued development of that real-time guidance layer.
Two Grants in One Month, and Why the Pattern Matters
The speed of these approvals is notable on its own terms. Pulsenmore secured its first AI-focused grant from the Israel Innovation Authority just weeks before this second award landed. While the company has not publicly broken down the exact scope of each grant’s technical mandate, the sequential approvals suggest the IIA is treating Pulsenmore’s AI roadmap as a multi-track program rather than a single-project bet. That kind of tiered public funding structure is increasingly common in deep-tech medtech, where the development timeline from prototype AI model to regulatory clearance can span years and requires sustained capital that venture rounds alone rarely cover.
For Pulsenmore, the funding arrives at a moment when remote patient monitoring is drawing serious commercial and regulatory attention globally. Prenatal care deserts — regions where access to in-person obstetric ultrasound is limited by distance, cost, or provider shortage — represent a genuine clinical problem with a measurable human cost. A device that can deliver reliable fetal monitoring at home, guided by AI, addresses that gap directly. The company has positioned SmartScan as infrastructure for that future, not just a convenience product. Whether the AI guidance system can meet the sensitivity and specificity thresholds that clinical adoption will demand remains the central technical question — but the grant trajectory suggests the IIA believes the architecture is worth backing at scale. As AI-dependent systems draw increasing scrutiny over reliability in high-stakes environments, Pulsenmore’s ability to demonstrate clinical-grade performance will define how far SmartScan can actually travel.
